1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01)" is currently closed and not accepting applications.
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This opportunity supports translational research in maternal and pediatric pharmacology and therapeutics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 865 -- Child Health and Human Development Extramural Research 93. 855 -- Allergy and Infectious Diseases Research 93.
242 -- Mental Health Research Grants 93. 279 -- Drug Use and Addiction Research Programs 93. 313 -- NIH Office of Research on Women's Health Last Updated: March 31, 2025 View version history on Grants.
gov The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant women, lactating women, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating women, neonates, and children.
The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women, fetuses, neonates, and children, including those with disabilities.
Federally recognized Native American tribal governments Public and Indian housing authorities City or township governments Special district governments Independent school districts Public and state institutions of higher education Private institutions of higher education For-profit organizations other than small businesses Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. File name Description Last updated PAR-25-110-Full-Announcement.
html PAR-25-110 Full Announcement Text Nov 18, 2024 06:53 PM UTC Link to additional information https://grants. nih. gov/grants/guide/pa-files/PAR-25-110.
html Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Income security and social services
According to the current listing, eligibility includes: Researchers and institutions. Confirm the full requirements in the official notice before applying.
The published deadline was January 1, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01) is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article